BRAF and cancer: Although N-terminal truncations of RAF are rare in human cancers, chromosomal translocations that delete the N-terminal regulatory domain of BRAF have been reported in multiple cancer types [7, 8] as well as aberrant spliced BRAF variants that delete the RAS binding domain in cells resistant to the BRAF inhibitor vemurafenib [9].